Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease

Digestive and Liver Disease

Volumn 48, Issue 4, 2016, Pages 360-370

  Armuzzi, Alessandro ^a   Gionchetti, Paolo ^b   Daperno, Marco ^c   Danese, Silvio ^d   Orlando, Ambrogio ^e   Lia Scribano, Maria ^f   Vecchi, Maurizio ^g   Rizzello, Fernando ^b   Ardizzone, Sandro ^h,i   Castiglione, Fabiana ^j   Fantini, Massimo ^c   Fiorino, Gionata ^k   Frieri, Giuseppe ^l   Neri, Luca ^g   Sturniolo, Giacomo Carlo ^m  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c MAURIZIANO HOSPITAL   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

^f SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h FATEBENEFRATELLI HOSPITAL   (Italy)

ⁱ AO L Sacco   (Italy)

^j UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^k UNIVERSITY OF ROME TOR VERGATA   (Italy)

^l UNIVERSITY OF L'AQUILA   (Italy)

^m Sita Messtechnik GmbH   (Germany)

more..

Author keywords

Crohn's Disease; Inflammatory Bowel Disease; Ulcerative Colitis; Vedolizumab

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; INTEGRIN RECEPTOR ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VEDOLIZUMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADAPTIVE IMMUNITY; BIOLOGICAL THERAPY; CROHN DISEASE; DISABILITY; DISEASE SEVERITY; DRUG TREATMENT FAILURE; HUMAN; INFLAMMATORY BOWEL DISEASE; MAINTENANCE THERAPY; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; DISEASE MANAGEMENT; INFLAMMATORY BOWEL DISEASES; PRACTICE GUIDELINE; PROCEDURES; SEVERITY OF ILLNESS INDEX;

ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL THERAPY; DISEASE MANAGEMENT; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84960796928     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.12.016     Document Type: Review

References (98)

1. Peyrin-Biroulet L., Cieza A., Sandborn W.J., et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012, 61:241-247.
2. Hanauer S.B. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflammatory Bowel Diseases 2006, 12(Suppl 1):S3-S9.
3. Cosnes J., Gower-Rousseau C., Seksik P., et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011, 140:1785-1794.
4. Tursi A., Elisei W., Picchio M. Incidence and prevalence of inflammatory bowel diseases in gastroenterology primary care setting. European Journal of Internal Medicine 2013, 24:852-856.
5. Di Domenicantonio R., Cappai G., Arcà M., et al. Occurrence of inflammatory bowel disease in central Italy: a study based on health information systems. Digestive and Liver Disease 2014, 46:777-782.
6. Hold G.L., Smith M., Grange C., et al. Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?. World Journal of Gastroenterology 2014, 20:1192-1210.
7. McLean L.P., Shea-Donohue T., Cross R.K. Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. Immunotherapy 2012, 4:883-898.
8. Howick J, Chalmers I, Glasziou P, et al. The 2011 Oxford CEBM levels of evidence. URL:. http://www.cebm.net/index.aspx?o=5653.
9. Dignass A., Van Assche G., Lindsay J.O., et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. Journal of Crohn's and Colitis 2010, 4:28-62.
10. Dignass A., Lindsay J.O., Sturm A., et al. Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis. Part 2: Current management. Journal of Crohn's and Colitis 2012, 6:991-1030.
11. Feagan B.G., Lémann M., Befrits R., et al. Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report. Inflammatory Bowel Diseases 2012, 18:152-160.
12. D'Haens G.R., Panaccione R., Higgins P.D., et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. American Journal of Gastroenterology 2011, 106:199-212.
13. Orlando A., Armuzzi A., Papi C., et al. The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease. Digestive and Liver Disease 2011, 43:1-20.
14. Mowat C., Cole A., Windsor A., et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011, 60:571-607.
15. Kornbluth A., Sachar D.B. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. American Journal of Gastroenterology 2010, 105:501-523. Practice Parameters Committee of the American College of Gastroenterology, quiz 524.
16. Ho G.T., Chiam P., Drummond H., et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Alimentary Pharmacology and Therapeutics 2006, 24:319-330.
17. Zenlea T., Peppercorn M.A. Immunosuppressive therapies for inflammatory bowel disease. World Journal of Gastroenterology 2014, 20:3146-3152.
18. Cohen B.L., Torres J., Colombel J.F. Immunosuppression in inflammatory bowel disease: how much is too much?. Current Opinion in Gastroenterology 2012, 28:341-348.
19. Behm B.W., Bickston S.J. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2008, 23:CD006893.
20. Lawson M.M., Thomas A.G., Akobeng A.K. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2006, 19:CD005112.
21. NICE technology appraisal guidance [TA329]. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) [Published February 2015/accessed March 2015]. ISBN 978-1-4731-1005-2.
22. Stidham R.W., Lee T.C., Higgins P.D., et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease. Alimentary Pharmacology and Therapeutics 2014, 39:1349-1362.
23. Danese S., Fiorino G., Peyrin-Biroulet L., et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Annals of Internal Medicine 2014, 160:704-711.
24. Gisbert J.P., González-Lama Y., Maté J. Systematic review: Infliximab therapy in ulcerative colitis. Alimentary Pharmacology and Therapeutics 2007, 25:19-37.
25. Ljung T., Karlén P., Schmidt D., et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004, 53:849-853.
26. Ford A.C., Sandborn W.J., Khan K.J., et al. Efficacy of biological therapies in inflammatory bowel disease. Systematic review and meta-analysis. American Journal of Gastroenterology 2011, 106:644-659.
27. Ben-Horin S., Chowers Y. Review article: Loss of response to anti-TNF treatments in Crohn's disease. Alimentary Pharmacology and Therapeutics 2011, 33:987-995.
28. Danese S., Fiorino G., Reinisch W. Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy. Alimentary Pharmacology and Therapeutics 2011, 34:1-10.
29. Benucci M., Li Gobbi F., Meacci F., et al. Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins. Biologics 2015, 9:7-12.
30. Lichtenstein G.R., Cohen R., Feagan B., et al. Safety of infliximab and other Crohn's disease therapies-TREAT registry data with nearly 24,575 patient-years of follow up [abstract]. American Journal of Gastroenterology 2008, 104(Suppl 1):5436.
31. Ali T., Kaitha S., Mahmood S., et al. Clinical use of anti-TNF therapy and increased risk of infections. Drug, Healthcare and Patient Safety 2013, 5:79-99.
32. Singh J.A., Wells G.A., Christensen R., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, 16:CD008794.
33. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. American Journal of Gastroenterology 2012, 107:1409-1422.
34. Caspersen S., Elkjaer M., Riis L., et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clinical Gastroenterology and Hepatology 2008, 6:1212-1217.
35. Herrinton L.J., Liu L., Chen L., et al. Association between anti-TNF-α therapy and all-cause mortality. Pharmacoepidemiology and Drug Safety 2012, 21:1311-1320.
36. Lichtenstein G.R., Rutgeerts P., Sandborn W.J., et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. American Journal of Gastroenterology 2012, 107:1051-1063.
37. Van Assche G., Lewis J.D., Lichtenstein G.R., et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. American Journal of Gastroenterology 2011, 106:1594-1602.
38. Cleynen I., Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nature Reviews Gastroenterology & Hepatology 2012, 9:496-503.
39. Denadai R., Teixeira F.V., Steinwurz F., et al. Induction or exacerbation of psoriatic lesions during anti-TNF-α therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. Journal of Crohn's and Colitis 2013, 7:517-524.
40. Niess J.H., Danese S. Anti-TNF and skin inflammation in IBD: a new paradox in gastroenterology?. Gut 2014, 63:533-535.
41. Chandar A.K., Singh S., Murad M.H., et al. Efficacy and safety of natalizumab and vedolizumab for the management of Crohn's disease: a systematic review and meta-analysis. Inflammatory Bowel Diseases 2015, 21:1695-1708.
42. Mosli M.H., MacDonald J.K., Bickston S.J., et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis. Inflammatory Bowel Diseases 2015, 21:1151-1159.
43. Allen P.B. Anti-adhesion molecules: is gut specificity the key for a good safety profile?. Current Drug Delivery 2012, 9:333-337.
44. Parikh A., Leach T., Wyant T., et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflammatory Bowel Diseases 2011, 18:1470-1479.
45. Feagan B.G., McDonald J., Greenberg G., et al. An ascending dose trial of humanized A4B7 antibody in ulcerative colitis. Gastroenterology 2000, 118(Suppl 2):A874.
46. Mosli M.H., Feagan B.G. Vedolizumab for Crohn's disease. Expert Opinion on Biological Therapy 2013, 13:455-463.
47. Feagan B.G., Rutgeerts P., Sands B.E., et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine 2013, 369:699-710.
48. Sandborn W.J., Feagan B.G., Rutgeerts P., et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. New England Journal of Medicine 2013, 369:711-721.
49. Sands B.E., Feagan B.G., Rutgeerts P., et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014, 147:618-627.
50. Wang M.C., Zhang L.Y., Han W., et al. PRISMA-efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. Medicine 2014, 93:e326.
51. Verbeeck J., Van Assche G., Ryding J., et al. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?. Gut 2008, 57:1393-1397.
52. Plavina T., Subramanyam M., Bloomgren G., et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Annals of Neurology 2014, 76:802-812.
53. Krupka N., Baumgart D.C. Designing biologic selectivity for inflammatory bowel disease-role of vedolizumab. Journal of Drug Design, Development and Therapy 2014, 9:147-154.
54. Planas R., Martin R., Sospedra M. Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life. Patient Related Outcome Measures 2014, 5:25-33.
55. Chebli L.A., Chaves L.D., Pimentel F.F., et al. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis. Inflammatory Bowel Diseases 2010, 16:613-619.
56. Faubion W.A., Loftus E.V., Harmsen W.S., et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255-260.
57. Bianchi Porro G., Cassinotti A., Ferrara E., et al. Review article: the management of steroid dependency in ulcerative colitis. Alimentary Pharmacology and Therapeutics 2007, 26:779-794.
58. Cassinotti A., Actis G.C., Duca P., et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. American Journal of Gastroenterology 2009, 104:2760-2767.
59. Zampeli E.L., Gizis M.L., Siakavellas S.I.L., et al. Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis. World Journal of Gastrointestinal Pathophysiology 2014, 5:293-303.
60. Ma C., Huang V., Fedorak D.K., et al. Outpatient ulcerative colitis primary anti-TNF responders receiving adalimumab or infliximab maintenance therapy have similar rates of secondary loss of response. Journal of Clinical Gastroenterology 2014, [Epub ahead of print].
61. Lakatos P.L., Miheller P. Is there an increased risk of lymphoma and malignancies under anti-TNF therapy in IBD?. Current Drug Targets 2010, 11:179-186.
62. Kuriyama M., Kato J., Fujimoto T., et al. Risk factors and indications for colectomy in ulcerative colitis patients are different according to patient's clinical background. Diseases of the Colon and Rectum 2006, 49:1307-1315.
63. Scand J., Solberg I.C., Lygren I., et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scandinavian Journal of Gastroenterology 2009, 44:431-440.
64. Desai A., Zator Z.A., de Silva P., et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflammatory Bowel Diseases 2013, 19:309-315. 10.1002/ibd.23026.
65. Cottone M., Kohn A., Daperno M., et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clinical Gastroenterology and Hepatology 2011, 9:30-35.
66. Reinisch W., Sandborn W.J., Hommes D.W., et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011, 60:780-787.
67. Rutgeerts P., Sandborn W.J., Feagan B.G., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine 2005, 353:2462-2476.
68. Sandborn W.J., Feagan B.G., Marano C., et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014, 146. 96-109.e1.
69. Sandborn W.J., van Assche G., Reinisch W., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012, 142. 257-65.e1-3.
70. Van Assche G., Vermeire S., Rutgeerts P. Treatment of severe steroid refractory ulcerative colitis. World Journal of Gastroenterology 2008, 14:5508-5511.
71. Colombel J.F., Rutgeerts P., Reinisch W., et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011, 141:1194-1201.
72. Timmer A., McDonald J.W., Macdonald J.K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2007, 24:CD000478.
73. Henriksen M., Jahnsen J., Lygren I., et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflammatory Bowel Diseases 2006, 12:543-550.
74. Bitton A., Peppercorn M.A., Antonioli D.A., et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001, 120:13-20.
75. Monstad I., Hovde O., Solberg I.C., et al. Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies. Annals of Gastroenterology 2014, 27:95-104.
76. Kane S., Huo D., Aikens J., et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. American Journal of Medicine 2003, 114:39-43.
77. Kane S.V., Cohen R.D., Aikens J.E., et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. American Journal of Gastroenterology 2001, 96:2929-2933.
78. Lopez A., Billioud V., Peyrin-Biroulet C., et al. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflammatory Bowel Diseases 2013, 19:1528-1533.
79. Selinger C.P., Robinson A., Leong R.W. Clinical impact and drivers of non-adherence to maintenance medication for inflammatory bowel disease. Expert Opinion on Drug Safety 2011, 10:863-870.
80. Ardizzone S., Maconi G., Russo A., et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006, 55:47-53.
81. Van Assche G., Dignass A., Panes J., et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Journal of Crohn's and Colitis 2010, 4:7-27.
82. Solberg I.C., Cvancarova M., Vatn M.H., et al. Risk matrix for prediction of advanced disease in a population-based study of patients with Crohn's Disease (the IBSEN Study). Inflammatory Bowel Diseases 2014, 20:60-68.
83. Eglinton T.W., Roberts R., Pearson J., et al. Clinical and genetic risk factors for perianal Crohn's disease in a population-based cohort. American Journal of Gastroenterology 2012, 107:589-596.
84. Baumgart D.C., Sandborn W.J. Crohn's disease. Lancet 2012, 380:1590-1605.
85. Chande N., Tsoulis D.J., MacDonald J.K. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2013, 4:CD000545.
86. Bonovas S., Moja L., Danese S. In the presence of conceptual heterogeneity, results of network meta-analysis comparing therapies in Crohn's disease need to be interpreted with caution. Gastroenterology 2015, 148:1483-1484.
87. Hazlewood G.S., Rezaie A., Borman M., et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn's disease: a network meta-analysis. Gastroenterology 2015, 148. 344-54.e5.
88. Steinhart A.H., Ewe K., Griffiths A.M., et al. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database of Systematic Reviews 2003, CD000301.
89. Camus M., Seksik P., Bourrier A., et al. Long-term outcome of patients with Crohn's disease who respond to azathioprine. Clinical Gastroenterology and Hepatology 2013, 11:389-394.
90. Peyrin-Biroulet L., Deltenre P., de Suray N., et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clinical Gastroenterology and Hepatology 2008, 6:644-653.
91. Shah E.D., Siegel C.A., Chong K., et al. Patients with Crohn's disease are more likely to remain on biologics than immunomodulators: a meta-analysis of treatment durability. Digestive Diseases and Sciences 2015, [Epub ahead of print].
92. De Boer N.K.h., Löwenberg M., Hoentjen F. Management of Crohn's disease in poor responders to adalimumab. Journal of Clinical and Experimental Gastroenterology 2014, 7:83-92.
93. Vermeire S., Noman M., Van Assche G., et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007, 56:1226-1231.
94. Ma C., Huang V., Fedorak D.K., et al. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study. Journal of Crohn's and Colitis 2014, 8:1454-1463.
95. Molnár T., Farkas K., Nyári T., et al. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period-a single center experience. Journal of Gastrointestinal and Liver Diseases 2012, 21:265-269.
96. Rutgeerts P., Feagan B.G., Lichtenstein G.R., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
97. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Annals of Internal Medicine 2007, 146:829-838.
98. Favalli E.G., Biggioggero M., Marchesoni A., et al. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology 2014, 53:1664-1668.